At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
Acylinedrug
Likely dose
Acyline 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Administration of the GnRH Antagonist Acyline in Normal Men Part II: Multiple-dose Pharmacokinetics (Acyline-7/MER 104-02)
In Brief
A Phase 2 clinical trial evaluating Acyline for Healthy. Completed, enrolled 4 participants across 1 site.
Detailed Summary
We propose oral dosing of gastrointestinal permeation enhancement technology \[GIPET\] enhanced oral acyline at 20 mg everyday for one week to determine the steady-state (multiple-dose) pharmacokinetics of oral acyline in four normal, healthy young men.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsMerrion Pharmaceuticals, LLC
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionFeb 2008
TodayJul 2026
First PostedJan 28, 2008
Enrollment StartJan 1, 2008
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 18.4 years ago
Interventions
Acylinedrug
20 mg GIPET enhanced oral dose, daily for 7-days